Innovation Pharmaceuticals Inc (IPIX)

[loanranger]

"A re-read of the endoscopies by the CRO's subcontractor and a subsequent fully blinded re-read of the endoscopies by an independent third party, Robarts Clinical Trials, confirmed that a subset of the initial endoscopy reads provided by the CRO were in error."

So your first guess at the issue apparently wasn't right:
("If the placebo clinical remission rate was 4 times normal, then that begs the question if some of the subjects that were thought to be on placebo were actual on the active trial treatment.")


Still misses the point, which was to ask whether the ultimate failure in the Prurisol trial couldn't have been averted by the conducting of the planned interim assessment.